Business Context and Reporting Period
This Form 8-K was filed by BIO-RAD LABORATORIES, INC. on December 9, 2009. The report addresses a corporate governance issue regarding the company's compliance with New York Stock Exchange (NYSE) listing standards.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing compliance matter and contains no financial performance data.
Material Changes
The material change reported is the receipt of official written notice from the NYSE on December 9, 2009. The Company is currently deficient in meeting Section 303A.07(a) of the NYSE Listed Company Manual, which mandates that a listed company maintain three independent directors on its audit committee. This deficiency stems from the previously reported resignation of Mr. Ruediger Naumann-Etienne from the Board of Directors.
Outlook, Risks, and Management Commentary
- Compliance Deadline: The Company must remedy the deficiency by December 16, 2009.
- Consequences of Non-Compliance: If the deficiency is not resolved by the deadline, the Company will be deemed noncompliant, and a "BC" (below compliance) indicator will be placed on its ticker symbol until compliance is regained.
- Management Action: The Company is actively seeking a replacement for Mr. Naumann-Etienne to serve on the Board of Directors and Audit Committee and intends to regain compliance as soon as practicable.
Key Facts for Investor Verification
- Verify if the Company successfully appointed a replacement director to the Audit Committee by December 16, 2009.
- Check subsequent filings to confirm whether the "BC" ticker indicator was applied or if compliance was restored.
- Review the composition of the Audit Committee to ensure it now meets the requirement of having three independent directors.